Alpa Laboratories Ltd

Alpa Laboratorie Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alpa Laboratories Ltd

₹ 89.0 -1.79%
04 Nov 12:38 p.m.
alpalabs.in BSE: 532878 NSE: ALPA
About

Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]

Key Points

Business Overview:[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use

Website BSE NSE
  • Market Cap ₹ 187 Cr.
  • Current Price ₹ 89.0
  • High / Low ₹ 137 / 85.0
  • Stock P/E 7.13
  • Book Value ₹ 81.5
  • Dividend Yield 0.00 %
  • ROCE 15.8 %
  • ROE 12.1 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 1.09 times its book value
  • Company has delivered good profit growth of 49.2% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 5.24% over past five years.
  • Company has a low return on equity of 11.4% over last 3 years.
  • Earnings include an other income of Rs.30.1 Cr.
  • Company has high debtors of 155 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
22 14 27 29 25 32 27 24 21 25 26 40 19
21 19 25 20 27 29 25 20 21 22 25 40 19
Operating Profit 1 -6 3 9 -1 3 2 4 1 3 1 0 0
OPM % 7% -42% 10% 32% -4% 10% 9% 15% 2% 13% 3% 0% 2%
2 6 3 -1 4 3 4 4 5 7 9 2 12
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 1 0 0 1 1 1 1 1 1 1
Profit before tax 3 0 5 8 3 6 5 7 5 10 9 2 12
Tax % 0% 0% 0% 42% 0% 0% 15% 47% 0% 20% 0% 202% 0%
3 0 5 5 3 6 5 4 5 8 9 -2 12
EPS in Rs 1.28 0.10 2.43 2.21 1.44 2.75 2.14 1.69 2.42 3.65 4.23 -1.01 5.59
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
56 57 53 63 62 77 85 97 112 93 109 110 110
51 54 47 56 58 76 80 90 101 85 100 105 105
Operating Profit 6 3 7 7 4 1 6 8 11 8 9 5 5
OPM % 10% 6% 13% 11% 7% 1% 7% 8% 10% 9% 8% 4% 4%
1 2 5 3 5 5 0 4 11 9 14 23 30
Interest 2 2 1 2 1 1 0 0 0 0 0 0 0
Depreciation 9 6 1 3 3 3 3 1 2 1 2 2 2
Profit before tax -5 -3 10 6 5 3 3 11 20 16 21 26 32
Tax % 4% -48% 30% 55% 39% 63% 36% 33% 28% 21% 19% 24%
-5 -1 7 3 3 1 2 7 14 13 17 20 26
EPS in Rs -2.45 -0.67 3.26 1.20 1.34 0.48 0.88 3.45 6.70 5.98 7.98 9.27 12.46
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 7%
5 Years: 5%
3 Years: -1%
TTM: 5%
Compounded Profit Growth
10 Years: 55%
5 Years: 49%
3 Years: 36%
TTM: 39%
Stock Price CAGR
10 Years: 11%
5 Years: 19%
3 Years: 16%
1 Year: -18%
Return on Equity
10 Years: 7%
5 Years: 10%
3 Years: 11%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 21 21 21 21 21 21 21 21 21 21 21 21
Reserves 67 66 72 74 77 77 79 87 101 114 131 150
23 29 24 11 6 2 0 0 6 2 5 0
15 13 27 20 18 21 21 33 28 30 25 51
Total Liabilities 127 128 144 126 122 121 121 140 155 167 182 223
73 5 15 15 10 8 6 7 9 7 11 21
CWIP 0 0 0 0 0 0 1 2 0 0 0 0
Investments 0 10 12 13 31 49 57 51 75 78 98 118
54 113 118 97 81 65 58 81 71 82 73 84
Total Assets 127 128 144 126 122 121 121 140 155 167 182 223

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
8 -2 -22 17 -13 -1 18 -2 10 9 4 18
-2 37 -8 -2 -11 -15 -11 6 -16 2 -13 -12
4 7 -6 -15 9 -5 -1 0 5 -4 3 -5
Net Cash Flow 10 42 -36 0 -15 -20 5 4 -0 7 -7 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 130 156 234 168 153 142 105 133 124 184 138 155
Inventory Days 148 76 196 131 138 105 90 102 81 84 73 92
Days Payable 121 91 244 140 134 99 98 152 78 100 63 97
Cash Conversion Cycle 157 141 187 159 157 149 97 83 127 168 149 150
Working Capital Days 65 -5 204 174 208 194 125 140 118 152 135 110
ROCE % 0% 10% 8% 6% 3% 5% 7% 9% 12% 15% 16%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29%
0.00% 0.00% 0.00% 0.11% 0.95% 0.50% 0.36% 0.74% 0.35% 0.40% 0.36% 0.35%
0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
42.70% 42.70% 42.70% 42.59% 41.74% 42.21% 42.35% 41.97% 42.34% 42.30% 42.34% 42.36%
No. of Shareholders 19,09419,13718,74518,56518,68218,69018,11618,88519,20618,87218,85118,542

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings